Overview of VBI-1501, VBI’s Cytomegalovirus (CMV) Vaccine Candidate
August 15, 2014 | Video
VBI is developing a prophylactic vaccine to prevent cytomegalovirus (“CMV”) infection. CMV is a leading cause of prenatal developmental delays. VBI has completed work for GMP manufacturing of its lead candidate for use in Phase I trials. VBI expects to evaluate safety, tolerability, and also immunological proof of concept in humans during Phase I trials by measuring CMV neutralizing antibodies in fibroblasts and epithelial cells.